Novo Seeds Portfolio Company IO Biotech Announces Positive Outcome of Interim Analysis of Phase 2 Trial in First Line Non-small Cell Lung Cancer

Novo Seeds, the early stage investment and company creation team of Novo Holdings, today announced that its portfolio company IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies based on its proprietary T-win® technology, announced the successful outcome of a scheduled interim analysis of the ongoing Phase 2 trial (IO102-012/KEYNOTE-764) of its lead cancer therapeutic vaccine, IO102, in non-small cell lung cancer (NSCLC).

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...